Drugs / ASLAN003
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02342652 | Oct 2014 → Mar 2015 | — | ASLAN Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01992367 | Aug 2013 → May 2014 | — | ASLAN Pharmaceuticals | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05865041 | Apr 2023 → Sep 2024 | alopecia areata | ASLAN Pharmaceuticals | Unknown | No outcome recorded |
| Phase 2 | NCT03451084 | Jan 2018 → Sep 2019 | acute myeloid leukemia | ASLAN Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASLAN003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01992367 ↗ |
| Known as | Farudodstat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05865041 ↗ |
| Action | Inhibit | “ASLAN003 (N-aryl substituted aminoaryloic acid derivative), which is a DHODH inhibitor” NCT02342652 ↗1“Dihydroorotate dehydrogenase inhibitor” CHEMBL2263632 ↗ |
| Modality | Small molecule | — CHEMBL2263632 ↗ |
| Route | Oral | “Administration route: Oral” NCT02342652 ↗ |
| Target | DHODH | “Dihydroorotate dehydrogenase inhibitor” CHEMBL2263632 ↗ |